STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 4] BELITE BIO, INC Insider Trading Activity

Belite Bio (BLTE) CSO sells 1,000 ADS in Rule 10b5-1 trades

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company on April 23, 2026. The sales were open-market transactions at prices ranging from about $164 to $170 per ADS and were executed under a Rule 10b5-1 trading plan adopted on 12/10/2025.

Positive

  • None.

Negative

  • None.
Insider MATA NATHAN L.
Role Chief Scientific Officer
Sold 1,000 shs ($166K)
Type Security Shares Price Value
Sale American depositary share 267 $164.4734 $44K
Sale American depositary share 158 $165.3759 $26K
Sale American depositary share 127 $166.5609 $21K
Sale American depositary share 373 $167.3743 $62K
Sale American depositary share 54 $168.4339 $9K
Sale American depositary share 21 $169.5567 $4K
Holdings After Transaction: American depositary share — 10,399 shares (Direct, null)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $164.03 to $164.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $165.02 to $165.915. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $166 to $166.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $167.01 to $167.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $168.15 to $168.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $169.55 to $169.69. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Total shares sold 1,000 American depositary shares Aggregate insider sales on April 23, 2026
Highest sale price $169.69 per ADS Upper end of disclosed weighted-average price range
Lowest sale price $164.03 per ADS Lower end of disclosed weighted-average price range
Individual transaction price example $169.5567 per ADS One reported open-market sale price on April 23, 2026
Rule 10b5-1 plan adoption date 12/10/2025 Date trading plan for these sales was adopted
ADS to ordinary share ratio 1 ADS = 1 ordinary share From Form 4 footnote on American depositary shares
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share"
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from $164.03 to $164.99"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MATA NATHAN L.
(Last)(First)(Middle)
7708 MARKER ROAD
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)04/23/2026S(2)267D$164.4734(3)10,399D
American depositary share(1)04/23/2026S(2)158D$165.3759(4)10,241D
American depositary share(1)04/23/2026S(2)127D$166.5609(5)10,114D
American depositary share(1)04/23/2026S(2)373D$167.3743(6)9,741D
American depositary share(1)04/23/2026S(2)54D$168.4339(7)9,687D
American depositary share(1)04/23/2026S(2)21D$169.5567(8)9,666D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. Represents the weighted average price of shares sold at prices that ranged from $164.03 to $164.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $165.02 to $165.915. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. Represents the weighted average price of shares sold at prices that ranged from $166 to $166.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. Represents the weighted average price of shares sold at prices that ranged from $167.01 to $167.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. Represents the weighted average price of shares sold at prices that ranged from $168.15 to $168.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
8. Represents the weighted average price of shares sold at prices that ranged from $169.55 to $169.69. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Nathan L. Mata04/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Belite Bio (BLTE) report in this Form 4?

Belite Bio reported that Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares in open-market transactions on April 23, 2026, according to the Form 4 insider trading report filed with the SEC.

At what prices did the Belite Bio (BLTE) CSO sell shares?

The Belite Bio Chief Scientific Officer sold 1,000 American depositary shares at weighted average prices between about $164 and $170 per share, with detailed ranges from $164.03 to $169.69 disclosed in the Form 4 footnotes.

Was the Belite Bio (BLTE) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025, indicating the transactions were pre-arranged rather than discretionary trades timed on the transaction date.

How many Belite Bio (BLTE) shares did the insider sell in total?

The insider sold a total of 1,000 American depositary shares, as summarized in the transaction data. Multiple sale entries on April 23, 2026 are reported, and the transaction summary aggregates them into a single net-sell amount of 1,000 shares.

What security class did the Belite Bio (BLTE) insider transactions involve?

All reported transactions involved Belite Bio American depositary shares. A footnote explains that each American depositary share represents one ordinary share of the issuer with a par value of US$0.0001 per share.

Who is the Belite Bio (BLTE) insider involved in this Form 4?

The reporting person is Nathan L. Mata, Belite Bio’s Chief Scientific Officer. The Form 4 identifies him as an officer of the company and shows that the reported sales were made from his direct holdings of American depositary shares.